Massimiliano Scalvenzi Selected Research

HhAntag691

1/2022	Vismodegib treatment in advanced basal cell carcinomas: Real-life experience.
12/2021	Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite other malignancies.
6/2021	Reflectance Confocal Microscopy Identification of Subclinical Basal Cell Carcinoma after Vismodegib Treatment: Report of a Case.
11/2020	Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation.
9/2020	Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study.
6/2020	Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.
1/2020	Reply to: "Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: A retrospective case series".
1/2020	Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas.
12/2019	Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).
9/2019	Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Massimiliano Scalvenzi Research Topics

Disease

24	Basal Cell Carcinoma (Rodent Ulcer) 01/2022 - 01/2019
11	Melanoma (Melanoma, Malignant) 06/2022 - 07/2005
8	Neoplasms (Cancer) 01/2022 - 02/2010
7	Skin Neoplasms (Skin Cancer) 01/2022 - 01/2018
6	Atopic Dermatitis (Atopic Eczema) 11/2022 - 11/2019
3	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2021 - 01/2011
3	Alopecia (Baldness) 11/2020 - 01/2011
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2022
2	Keratoacanthoma 12/2021 - 06/2019
2	Eczema 04/2021 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2014 - 02/2010
1	Paralysis (Palsy) 01/2022
1	Spasm (Spasms) 01/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2022
1	Lymphomatoid Papulosis 01/2022
1	Chronic Disease (Chronic Diseases) 11/2021
1	Rhinosinusitis 11/2021
1	Nasal Polyps (Nasal Polyp) 11/2021
1	Exanthema (Rash) 10/2021
1	Cicatrix (Scar) 06/2021
1	Hypoxia (Hypoxemia) 01/2021
1	COVID-19 11/2020
1	Prurigo 01/2020
1	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2020
1	Pruritus (Itching) 01/2020
1	Lymphatic Metastasis 06/2019
1	Merkel Cell Carcinoma 06/2019
1	Benign Familial Pemphigus (Hailey Hailey Disease) 01/2019
1	Cysts 01/2017
1	Acne Vulgaris 01/2011
1	Rosacea (Acne Rosacea) 01/2011
1	Hypertrophic Cicatrix (Hypertrophic Scar) 01/2011
1	Allergic Contact Dermatitis 05/2010
1	Drug Eruptions (Drug Eruption) 10/2009
1	Parasitic Skin Diseases 09/2009
1	Alternariosis 01/2008
1	Cutaneous Malignant Melanoma 07/2005
1	Genomic Instability 07/2005

Drug/Important Bio-Agent (IBA)

11	HhAntag691IBA 01/2022 - 01/2019
10	sonidegibIBA 01/2022 - 06/2020
6	dupilumabIBA 11/2022 - 11/2019
6	Pharmaceutical PreparationsIBA 01/2022 - 10/2009
2	Monoclonal AntibodiesIBA 01/2022 - 01/2022
2	cemiplimabIBA 01/2022 - 01/2022
2	Biological ProductsIBA 01/2021 - 07/2005
2	Proteins (Proteins, Gene)FDA Link 02/2010 - 07/2005
1	VaccinesIBA 06/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	NivolumabIBA 01/2022
1	Vincristine (Oncovin)FDA LinkGeneric 01/2022
1	IpilimumabIBA 01/2022
1	pembrolizumabIBA 01/2022
1	Ciprofloxacin (Cipro)FDA LinkGeneric 10/2021
1	talimogene laherparepvecIBA 06/2021
1	Carbonic Anhydrase IXIBA 01/2021
1	3-ingenyl angelateIBA 10/2019
1	Methotrexate (Mexate)FDA LinkGeneric 06/2019
1	Vitamin D FDA LinkGeneric 01/2019
1	Imiquimod (Aldara)FDA LinkGeneric 12/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2017
1	Interleukin-6 (Interleukin 6)IBA 04/2017
1	Interferon-gamma (Interferon, gamma)IBA 04/2017
1	Keratins (Keratin)IBA 01/2017
1	ImmunophilinsIBA 07/2015
1	Protein Isoforms (Isoforms)IBA 07/2015
1	Messenger RNA (mRNA)IBA 01/2014
1	CytokinesIBA 01/2014
1	RetinoidsIBA 01/2011
1	Acitretin FDA Link 01/2011
1	Betaxolol (Kerlon)FDA LinkGeneric 05/2010
1	Ophthalmic Solutions (Eye Drops)IBA 05/2010
1	Timolol (Blocadren)FDA LinkGeneric 05/2010
1	Chromatin Assembly Factor-1IBA 02/2010
1	Acetaminophen (Paracetamol)FDA LinkGeneric 10/2009
1	Poly Adenosine Diphosphate RiboseIBA 07/2005
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 07/2005

Therapy/Procedure

14	Therapeutics 06/2022 - 01/2008
5	Radiotherapy 11/2020 - 06/2019
2	Drug Therapy (Chemotherapy) 01/2022 - 06/2019
1	Immunotherapy 06/2022
1	Photochemotherapy (Photodynamic Therapy) 01/2022
1	Tattooing 12/2021
1	Drug Tapering 01/2021
1	Aftercare (After-Treatment) 01/2020
1	Kidney Transplantation 01/2008